Literature DB >> 18637888

Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France.

Mariam Molokhia1, Atul Pathak, Maryse Lapeyre-Mestre, Laetitia Caturla, Jean Louis Montastruc, Paul McKeigue.   

Abstract

AIMS: The aim of this study was to investigate the incidence and reporting rate of drug-induced long-QT syndrome (LQTS) in France [defined by evidence of torsades de pointes (TdP), QT prolongation and exposure to a relevant drug] and to assess feasibility of case collection for drug-induced LQTS.
METHODS: A retrospective population-based study was carried out in Southwest France in five institutions: three main hospitals, one private clinic and one cardiac emergency unit, searched from 1 January 1999 to 1 January 2005 (population coverage of 614 000). The study population consisted of 861 cases with International Classification of Diseases-10 diagnostic codes for ventricular tachycardia (I147.2), ventricular fibrillation (I149.0) and sudden cardiac death (I146.1) from hospital discharge summaries, supplemented by cases reported to national or regional pharmacovigilance systems, and voluntary reporting by physicians, validated according to internationally defined criteria for drug-induced LQTS.
RESULTS: Of 861 patients coded with arrhythmias or sudden cardiac death, there were 40 confirmed surviving acquired cases of drug-induced LQTS. We estimated that the incidence of those who survive to reach hospital drug-induced LQTS is approximately 10.9 per million annually in France (95% confidence interval 7.8, 14.8).
CONCLUSIONS: Many cases of drug-induced LQTS may not survive before they reach hospital, as the reporting rate for drug-induced LQTS identified through the cardiology records and also reported to pharmacovigilance systems for the Midi-Pyrenees area is 3/40 (7.5%). Using the methods outlined it is possible to assemble cases to study genetic susceptibility to drug-induced LQTS and adapt these methods more widely.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637888      PMCID: PMC2526236          DOI: 10.1111/j.1365-2125.2008.03229.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities.

Authors:  A John Camm
Journal:  Fundam Clin Pharmacol       Date:  2002-04       Impact factor: 2.748

2.  Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland.

Authors:  D N Bateman; A M Good; R Afshari; C A Kelly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

3.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

4.  Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features.

Authors:  R Tawil; L J Ptacek; S G Pavlakis; D C DeVivo; A S Penn; C Ozdemir; R C Griggs
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

Review 5.  Recent advances in understanding sex differences in cardiac repolarization.

Authors:  Andrew F James; Stéphanie C M Choisy; Jules C Hancox
Journal:  Prog Biophys Mol Biol       Date:  2005-06-13       Impact factor: 3.667

6.  Thioridazine and sudden unexplained death in psychiatric in-patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H L Thomas
Journal:  Br J Psychiatry       Date:  2002-06       Impact factor: 9.319

7.  Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.

Authors:  Peter J Mohler; Jean-Jacques Schott; Anthony O Gramolini; Keith W Dilly; Silvia Guatimosim; William H duBell; Long-Sheng Song; Karine Haurogné; Florence Kyndt; Mervat E Ali; Terry B Rogers; W J Lederer; Denis Escande; Herve Le Marec; Vann Bennett
Journal:  Nature       Date:  2003-02-06       Impact factor: 49.962

Review 8.  Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.

Authors:  Jean T Barbey; Ralph Lazzara; Douglas P Zipes
Journal:  J Cardiovasc Pharmacol Ther       Date:  2002-04       Impact factor: 2.457

9.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.

Authors:  Aimée D C Paulussen; Ronaldus A H J Gilissen; Martin Armstrong; Pieter A Doevendans; Peter Verhasselt; Hubert J M Smeets; Eric Schulze-Bahr; Wilhelm Haverkamp; Günter Breithardt; Nadine Cohen; Jeroen Aerssens
Journal:  J Mol Med (Berl)       Date:  2004-02-04       Impact factor: 4.599

Review 10.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more
  18 in total

1.  Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 2.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

3.  Drug-induced long QT syndrome and drug development.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

4.  Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Igor Diemberger; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

Review 5.  Drug-induced arrhythmia: pharmacogenomic prescribing?

Authors:  Elijah R Behr; Dan Roden
Journal:  Eur Heart J       Date:  2012-10-22       Impact factor: 29.983

Review 6.  [Proarrhythmic adverse effects of nonarrhythmic drugs].

Authors:  C G Jungbauer; L S Maier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-08-23

Review 7.  Algorithms used to identify ventricular arrhythmias and sudden cardiac death in retrospective studies: a systematic literature review.

Authors:  Yizhou Ye; E Paul Larrat; Aisling R Caffrey
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-12-11

8.  Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.

Authors:  Sylvain Goutelle; Elodie Sidolle; Michel Ducher; Jacques Caron; Quadiri Timour; Patrice Nony; Aurore Gouraud
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

Review 9.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

10.  Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.

Authors:  G Michels; M Kochanek; R Pfister
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-04       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.